^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    navitoclax (ABT 263) (Bcl2 inhibitor, Bcl-xL inhibitor, Bcl-w inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Am J Cancer Res
    Title:

    KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations

    Published date:
    12/01/2020
    Excerpt:
    The disease control rates in KRAS-mutant PDXs tested were 90%-100% after treatment with trametinib plus KRT-232 or plus navitoclax. 
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 557: Novel targeted combination therapies active in KRAS mutant non-small cell lung cancer (NSCLC) identified using patient-derived xenografts (PDX)

    Published date:
    05/15/2020
    Excerpt:
    Our results show that combination therapies of trametinib plus KRT-232 or navitoclax result in improved efficacy in a subgroup of NSCLC PDX models with KRAS mutations.
    DOI:
    10.1158/1538-7445.AM2020-557